NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Conditions: Covid19
Interventions: COVID-19 vaccine Pfizer (3 doses), COVID-19 vaccine Pfizer (2 doses), COVID-19 mRNA Vaccine Moderna (3 doses), COVID-19 mRNA Vaccine Moderna (2 doses), COVID-19 mRNA Vaccine Moderna (1 dose)
Countries: France
Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population. However, immunosenescence appears to play a role in the natural post-COVID-19 immunity of convalescent elderly subjects and also in the post-vaccination response. However, vaccination recommendations for both naïve (2 doses of vaccine) and convalescent subjects (1 dose of vaccine) do not differ according to age. To date, there is little data to suggest that the response to the vaccine in naïve or convalescent subjects may vary according to age in terms of qualitative and quantitative response and duration.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * For the group with a past history of COVID-19 (convalescents)= subject within ≥ 3 months after infection * For the NO past history of COVID-19 (naives), subject with no known history of COVID-19 * Patient affiliated or entitled to a social security plan * Patients who have received informed information about the study and who have co-signed a consent to participate in the study with the investigator Exclusion Criteria: * Immunocompromised or under immunosuppressive treatment * Subject with a history of COVID hospitalized in intensive care * Subject allergic to one of the components of the vaccines used in the study * subject vaccinated for COVID-19 * Subject with persistent symptoms of COVID-19 (long COVID) * Subjects with unstable chronic pathology * Persons deprived of liberty, hospitalized without consent * Pregnant or breastfeeding woman
- Lyon, France
- Saint-Etienne, France